The utility of Pax-2 and renal cell carcinoma marker immunohistochemistry in distinguishing papillary renal cell carcinoma from nonrenal cell neoplasms with papillary features

Applied Immunohistochemistry and Molecular Morphology

Volumn 18, Issue 6, 2010, Pages 494-498

  Sharma, Shree G ^a   Gokden, Murat ^a   McKenney, Jesse K ^b   Phan, Dan C ^a   Cox, Roni Michelle ^a   Kelly, Thomas ^a   Gokden, Neriman ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

papillary renal cell carcinoma; PAX 2; renal cell carcinoma marker

Indexed keywords

RENAL CELL CARCINOMA MARKER; TRANSCRIPTION FACTOR PAX2; TUMOR MARKER; UNCLASSIFIED DRUG;

ARTICLE; CANCER DIAGNOSIS; CANCER OF UNKNOWN PRIMARY SITE; CHOROID PLEXUS PAPILLOMA; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; FEMALE; HUMAN; HUMAN TISSUE; HYPOPHYSIS ADENOMA; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; INTRADUCTAL PAPILLARY MUCINOUS CARCINOMA OF THE PANCREAS; KIDNEY CARCINOMA; LUNG ADENOCARCINOMA; METASTASIS; OVARIAN PAPILLARY SEROUS CARCINOMA; PAPILLARY CARCINOMA; PAPILLARY RENAL CELL CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENSITIVITY AND SPECIFICITY; THYROID PAPILLARY CARCINOMA; UTERINE PAPILLARY SEROUS CARCINOMA;

ANTIGENS, NEOPLASM; BIOPSY; CARCINOMA, PAPILLARY; CARCINOMA, RENAL CELL; CELL NUCLEUS; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KIDNEY; KIDNEY NEOPLASMS; MITOGEN-ACTIVATED PROTEIN KINASES; NEOPLASM METASTASIS; PAX2 TRANSCRIPTION FACTOR; PREDICTIVE VALUE OF TESTS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 78650424043     PISSN: 15412016     EISSN: 15334058     Source Type: Journal    
DOI: 10.1097/PAI.0b013e3181e78ff8     Document Type: Article

References (28)

1. Wahner-Roedler DL, Sebo TJ. Renal cell carcinoma: diagnosis based on metastatic manifestations. Mayo Clin Proc. 1997;72: 935-941. (Pubitemid 27459429)
2. Chowdhury S, Choueiri TK. Recent advances in the systemic treatment of metastatic papillary renal cancer. Expert Rev Anticancer Ther. 2009;9:373-379.
3. Ronnen EA, Kondagunta GV, Ishill N, et al. Treatment outcome for metastatic papillary renal cell carcinoma patients. Cancer. 2006;107:2617-2621. (Pubitemid 44845616)
4. Bakshi N, Kunju LP, Giordano T, et al. Expression of renal cell carcinoma antigen (RCC) in renal epithelial and nonrenal tumors: Diagnostic implications. Appl Immunohistochem Mol Morphol. 2007;15:310-315. (Pubitemid 47329924)
5. Gokden N, Mukunyadzi P, James JD, et al. Diagnostic utility of renal cell carcinoma marker in cytopathology. Appl Immunohistochem Mol Morphol. 2003;11:116-119. (Pubitemid 36749562)
6. Gokden N, Gokden M, Phan DC, et al. The utility of PAX-2 in distinguishing metastatic clear cell renal cell carcinoma from its morphologic mimics: an immunohistochemical study with comparison to renal cell carcinoma marker. Am J Surg Pathol. 2008; 32:1462-1467.
7. Rothenpieler UW, Dressler GR. Pax-2 is required for mesenchymeto- epithelium conversion during kidney development. Development. 1993;119:711-720.
8. Oefelein M, Grapey D, Schaeffer T, et al. Pax-2: a developmental gene constitutively expressed in the mouse epididymis and ductus deferens. J Urol. 1996;156:1204-1207. (Pubitemid 26269857)
9. Daniel L, Lechevallier E, Giorgi R, et al. Pax-2 expression in adult renal tumors. Hum Pathol. 2001;32:282-287. (Pubitemid 32246801)
10. Mazal PR, Stichenwirth M, Koller A, et al. Expression of aquaporins and PAX-2 compared to CD10 and cytokeratin 7 in renal neoplasms: a tissue microarray study. Mod Pathol. 2005; 18:535-540. (Pubitemid 40478117)
11. Memeo L, Jhang J, Assaad AM, et al. Immunohistochemical analysis for cytokeratin 7, KIT, and PAX2: value in the differential diagnosis of chromophobe cell carcinoma. Am J Clin Pathol. 2007;127:225-229. (Pubitemid 46797179)
12. Gupta R, Balzer B, Picken M, et al. Diagnostic implications of transcription factor Pax-2 protein and transmembrane enzyme complex carbonic anhydrase IX immunoreactivity in adult renal epithelial neoplasms. Am J Surg Pathol. 2009;33:241-247.
13. Ozcan A, Zhai J, Hamilton C, et al. PAX-2 in the diagnosis of primary renal tumors: immunohistochemical comparison with renal cell carcinoma marker antigen and kidney-specific cadherin. Am J Clin Pathol. 2009;131:393-404.
14. Zhai QJ, Ozcan A, Hamilton C, et al. Pax-2 expression in nonneoplastic, primary neoplastic, and metastatic neoplastic tissue: a comprehensive immunohistochemical study. Appl Immunohistochem Mol Morphol. 2010;18:323-332.
15. McGregor DK, Khurana KK, Cao C, et al. Diagnosing primary and metastatic renal cell carcinoma: the use of the monoclonal antibody renal cell carcinoma marker. Am J Surg Pathol. 2001;25: 1485-1492. (Pubitemid 33096962)
16. Avery AK, Beckstead J, Renshaw AA, et al. Use of antibodies to RCC and CD10 in the differential diagnosis of renal neoplasms. Am J Surg Pathol. 2000;24:203-210. (Pubitemid 30078709)
17. Chu P, Wu E, Weiss LM. Cytokeratin 7 and cytokeratin 20 expression in epithelial neoplasms: a survey of 435 cases. Mod Pathol. 2000;13:962-972.
18. Chu P, Arber DA. Paraffin-section detection of CD10 in 505 nonhematopoietic neoplasms; frequent expression in renal cell carcinoma and endometrial stromal sarcoma. Am J Clin Pathol. 2000;113:374-382. (Pubitemid 30217385)
19. Ramaekers FC, Haag D, Kant A, et al. Coexpression of keratinand vimentin- type intermediate filaments in human metastatic carcinoma cells. Proc Natl Acad Sci USA. 1983;80:2618-2622. (Pubitemid 13093360)
20. Miettinen M, Franssila K, Lehto VP, et al. Expression of intermediate filament proteins in thyroid gland and thyroid tumors. Lab Invest. 1984;50:262-270. (Pubitemid 14154637)
21. McNutt MA, Bolen JW, Gown AM, et al. Coexpression of intermediate filaments in human epithelial neoplasms. Ultrastruct Pathol. 1985;9:31-43. (Pubitemid 16189760)
22. Dabbs DJ, Geisinger KR, Norris HT. Intermediate filaments in endometrial and endocervical carcinomas. The diagnostic utility of vimentin patterns. Am J Surg Pathol. 1986;10:568-576.
23. Tong GX, Chiriboga L, Hamele-Bena D, et al. Expression of PAX2 in papillary serous carcinoma of the ovary: immunohistochemical evidence of fallopian tube or secondary mullerian system origin? Mod Pathol. 2007;20:856-863. (Pubitemid 47077268)
24. Gnarra JR, Dressler GR. Expression of pax-2 in human renal cell carcinoma and growth inhibition by antisense oligonucleotides. Cancer Res. 1995;55:4092-4098.
25. Igarashi T, Ueda T, Suzuki H, et al. Aberrant expression of pax-2 mRNA in renal cell carcinoma tissue and parenchyma of the affected kidney. Int J Urol. 2001;8:60-64. (Pubitemid 32245344)
26. Liebovich BC, Sheinin Y, Lohse CM, et al. Carbonic anhydrase IX is not an independent predictor of outcome for patients with clear cell renal cell carcinoma. J Clin Oncol. 2007; 25:4757-4764. (Pubitemid 350086478)
27. Huang Y, Murakami T, Sano F, et al. Expression of aquaporin 1 in primary renal tumors:a prognostic indicator for clear cell renal cell carcinoma. Eur Urol. 2009;56:690-698.
28. Skinnider BF, Amin MB. An immunohistochemical approach to the differential diagnosis of renal tumors. Semin Diagn Pathol. 2005; 22:51-68. (Pubitemid 43163179)